Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ART-123 in DIC Patients with Renal Impairment
NCT01704001Phase 4Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Oct 2012
- Primary completion
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of thrombomodulin alfa in disseminated intravascular coagulation (DIC) (4 arms), sponsored by Asahi Kasei Corporation. Primary endpoints: Composite of Pharmacokinetics and Incidence rate of hemorrhage related adverse events. Started Oct 2012; status: completed.
02
Drugs
thrombomodulin alfa
03
Conditions
disseminated intravascular coagulation (DIC)
Beyond the preview
Go deeper on NCT01704001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704001.